Clinical Trials Logo

Clinical Trial Summary

This is a randomized, single-blind, single-center study comparing calculated total blood loss, surgical drain output and hematoma formation in anticoagulated patients who receive 2 doses of Tranexamic Acid (TXA) versus control group undergoing anatomical and reverse total shoulder arthroplasty (TSA). Patients will be randomized to either receive 2 doses of IV TXA, first dose prior to surgical incision and second dose given 3 hours later or to the control group, where no TXA will be administered.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT04560010
Study type Interventional
Source NYU Langone Health
Status Terminated
Phase Phase 4
Start date October 6, 2020
Completion date March 11, 2023